Novo Nordisk A/S (NOVO B.CO) stock: key figures, P/E, revenue and dividend
Health Care · Denmark · ISIN DK0062498333
Novo Nordisk A/S financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 290.40 bn DKK | 309.06 bn DKK |
| Gross profit | 246.84 bn DKK | 250.28 bn DKK |
| Operating income | 138.90 bn DKK | 140.62 bn DKK |
| EBIT | 138.90 bn DKK | 127.66 bn DKK |
| Net income | 100.99 bn DKK | 102.43 bn DKK |
| Diluted EPS – continuing operations | 22.63 DKK | 23.03 DKK |
Full history since 1985, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
More stocks
- Deere & Company (DE)
- SoftBank Group Corp (9984.T)
- Abb Ltd (ABBN.SW)
- Rio Tinto Ltd (RIO.AX)
- BlackRock (BLK)
- ConocoPhillips (COP)
- McDonald's (MCD)
- Union Pacific Corporation (UNP)
- Novo Nordisk A/S (NVO)
- Schneider Electric SE (SU.PA)
- T-Mobile US (TMUS)
- Airbus SE (AIR.PA)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.